The Europe Molecular Quality Controls Market is expected to witness market growth of 6.4% CAGR during the forecast period (2022-2028).
In vitro nucleic acid testing processes for viral load assays, healthcare-related illnesses, and infections linked with sexually transmitted diseases benefit from Molecular Quality Controls. These quality controls are primarily concerned with testing molecular diagnostic items in order to detect faults and report them to management. This has an impact on the decision to release or not release the product. By enabling labs to apply the latest QC procedures and powerful data management tools, the growing variety of molecular quality control systems makes it easy to accomplish risk reduction goals.
The proliferation of cancer research and related biomarkers is a primary driver of the rise in the demand for molecular quality controls in Europe. According to a study presented at the European Society of Medical Oncology's annual meeting, cancer incidence will grow by about 21% between 2020 and 2040. Efforts to uncover biomarkers are also accelerating, as seen by Roche's announcement of the AVENIO Tumor Tissue CGP Kit expected to release in October 2021, which is aimed to help labs boost in-house oncology research. Europe has been a major force in molecular quality controls and the trend is likely to continue in the near future. The rise in the number of contract research organizations and the demand for third-party quality control help is driving the growth of the molecular quality controls Market in the area.
The European Molecular Genetics Quality Network (EMQN) was founded in 1996 with the goal of spreading QA standards throughout Europe and harmonizing existing state operations. EMQN encourages quality assurance through two methods: disease-specific best practice meetings (BPM) and EQA programs.
The Germany Market dominated the Europe Molecular Quality Controls Market by Country 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $17.2 million by 2028. The UK Market is estimated to grow at a CAGR of 5.5% during (2022-2028). Additionally, The France Market is expected to experience a CAGR of 7.2% during (2022-2028).
Based on Analyte Type, the Market is segmented into Single-analyte Controls and Multi-analyte Controls. Based on Application, the Market is segmented into Infectious Diseases Diagnostics, Oncology Testing, Genetic Testing, and Others. Based on Product, the Market is segmented into Independent Controls and Instrument-specific Controls (PCR, DNA Sequencing & NGS, and Others). Based on End User, the Market is segmented into Diagnostic Laboratories, Hospitals, IVD Manufacturers & CROs, Academic & Research Institutes, and Others. Based on countries, the Market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Grifols, S.A, Abbott Laboratories, Quidel Corporation, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Seegene, Inc., Randox Laboratories Limited, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, and Microbiologics, Inc.
By Analyte Type
By Country
In vitro nucleic acid testing processes for viral load assays, healthcare-related illnesses, and infections linked with sexually transmitted diseases benefit from Molecular Quality Controls. These quality controls are primarily concerned with testing molecular diagnostic items in order to detect faults and report them to management. This has an impact on the decision to release or not release the product. By enabling labs to apply the latest QC procedures and powerful data management tools, the growing variety of molecular quality control systems makes it easy to accomplish risk reduction goals.
The proliferation of cancer research and related biomarkers is a primary driver of the rise in the demand for molecular quality controls in Europe. According to a study presented at the European Society of Medical Oncology's annual meeting, cancer incidence will grow by about 21% between 2020 and 2040. Efforts to uncover biomarkers are also accelerating, as seen by Roche's announcement of the AVENIO Tumor Tissue CGP Kit expected to release in October 2021, which is aimed to help labs boost in-house oncology research. Europe has been a major force in molecular quality controls and the trend is likely to continue in the near future. The rise in the number of contract research organizations and the demand for third-party quality control help is driving the growth of the molecular quality controls Market in the area.
The European Molecular Genetics Quality Network (EMQN) was founded in 1996 with the goal of spreading QA standards throughout Europe and harmonizing existing state operations. EMQN encourages quality assurance through two methods: disease-specific best practice meetings (BPM) and EQA programs.
The Germany Market dominated the Europe Molecular Quality Controls Market by Country 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $17.2 million by 2028. The UK Market is estimated to grow at a CAGR of 5.5% during (2022-2028). Additionally, The France Market is expected to experience a CAGR of 7.2% during (2022-2028).
Based on Analyte Type, the Market is segmented into Single-analyte Controls and Multi-analyte Controls. Based on Application, the Market is segmented into Infectious Diseases Diagnostics, Oncology Testing, Genetic Testing, and Others. Based on Product, the Market is segmented into Independent Controls and Instrument-specific Controls (PCR, DNA Sequencing & NGS, and Others). Based on End User, the Market is segmented into Diagnostic Laboratories, Hospitals, IVD Manufacturers & CROs, Academic & Research Institutes, and Others. Based on countries, the Market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Grifols, S.A, Abbott Laboratories, Quidel Corporation, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Seegene, Inc., Randox Laboratories Limited, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, and Microbiologics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Analyte Type
- Single-analyte Controls
- Multi-analyte Controls
- Infectious Diseases Diagnostics
- Oncology Testing
- Genetic Testing
- Others
- Independent Controls
- Instrument-specific Controls
- PCR
- DNA Sequencing & NGS
- Others
- Diagnostic Laboratories
- Hospitals
- IVD Manufacturers & CROs
- Academic & Research Institutes
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Grifols, S.A
- Abbott Laboratories
- Quidel Corporation
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Seegene, Inc.
- Randox Laboratories Limited
- F. Hoffmann-La Roche Ltd.
- Bio-Techne Corporation
- Microbiologics, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Europe Molecular Quality Controls Market by Analyte Type
Chapter 5. Europe Molecular Quality Controls Market by Application
Chapter 6. Europe Molecular Quality Controls Market by Product
Chapter 7. Europe Molecular Quality Controls Market by End User
Chapter 8. Europe Molecular Quality Controls Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Grifols, S.A
- Abbott Laboratories
- Quidel Corporation
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Seegene, Inc.
- Randox Laboratories Limited
- F. Hoffmann-La Roche Ltd.
- Bio-Techne Corporation
- Microbiologics, Inc.
Methodology
LOADING...
